[go: up one dir, main page]

BR0208727A - Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia - Google Patents

Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia

Info

Publication number
BR0208727A
BR0208727A BR0208727-8A BR0208727A BR0208727A BR 0208727 A BR0208727 A BR 0208727A BR 0208727 A BR0208727 A BR 0208727A BR 0208727 A BR0208727 A BR 0208727A
Authority
BR
Brazil
Prior art keywords
erythropoietin
induced
vivo toxicity
toxicity
improving chemotherapy
Prior art date
Application number
BR0208727-8A
Other languages
English (en)
Inventor
George Sigounas
Paul Mehlhop
Original Assignee
Univ East Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0208727(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ East Carolina filed Critical Univ East Carolina
Publication of BR0208727A publication Critical patent/BR0208727A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"ERITROPOIETINA MELHORANDO A TOXICIDADE IN VIVO INDUZIDA POR QUIMIOTERAPIA". A invenção refere-se a um método para reduzir a toxicidade de órgão em um indivíduo sendo administrado por um agente citotóxico, compreendendo administrar concorrentemente com o agente citotóxico, a eritropoietina (EPO), sendo a EPO administrada em uma quantidade eficaz para reduzir a toxicidade pulmonar causada pelo agente citotóxico.
BR0208727-8A 2001-04-09 2002-04-08 Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia BR0208727A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28262101P 2001-04-09 2001-04-09
PCT/US2002/011081 WO2002080676A1 (en) 2001-04-09 2002-04-08 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Publications (1)

Publication Number Publication Date
BR0208727A true BR0208727A (pt) 2005-05-10

Family

ID=23082337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208727-8A BR0208727A (pt) 2001-04-09 2002-04-08 Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia

Country Status (22)

Country Link
US (2) US20020169128A1 (pt)
EP (1) EP1377164B1 (pt)
JP (1) JP4428924B2 (pt)
KR (1) KR100885525B1 (pt)
CN (2) CN101152565A (pt)
AT (1) ATE399020T1 (pt)
AU (1) AU2002256133B2 (pt)
BR (1) BR0208727A (pt)
CA (1) CA2443025A1 (pt)
DE (1) DE60227244D1 (pt)
DK (1) DK1377164T3 (pt)
ES (1) ES2309166T3 (pt)
HU (1) HUP0303838A3 (pt)
IL (3) IL158155A0 (pt)
MX (1) MXPA03009182A (pt)
NO (1) NO20034504L (pt)
NZ (1) NZ528675A (pt)
PL (1) PL373361A1 (pt)
PT (1) PT1377164E (pt)
RU (1) RU2296563C2 (pt)
WO (1) WO2002080676A1 (pt)
ZA (1) ZA200307803B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20030199043A1 (en) 2000-04-12 2003-10-23 Ballance David J. Albumin fusion proteins
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
CA2525399A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
OA13164A (en) 2003-05-12 2006-12-13 Affymax Inc Novel peptides that bind to the erythropoietin receptor.
KR101227666B1 (ko) * 2003-05-12 2013-01-31 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 펩티드
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2587382A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2057997A4 (en) * 2006-08-22 2012-11-07 Chugai Pharmaceutical Co Ltd MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
EP1992355A1 (en) * 2007-05-16 2008-11-19 Eberhardt Spanuth Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs
ES2917884T3 (es) * 2015-06-18 2022-07-12 Yeda Res & Dev Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos
US10695402B2 (en) 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859765A (en) * 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) * 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) * 1987-01-22 1988-12-30 Erga Srl Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4856871A (en) * 1987-08-31 1989-08-15 General Electric Company Replaceable laser and lens assembly
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
HUP0300333A3 (en) * 1999-05-11 2009-01-28 Ortho Mcneil Pharm Inc Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs

Also Published As

Publication number Publication date
IL158155A0 (en) 2004-03-28
RU2296563C2 (ru) 2007-04-10
ZA200307803B (en) 2005-02-09
AU2002256133B2 (en) 2007-05-31
JP2004532840A (ja) 2004-10-28
KR20030087064A (ko) 2003-11-12
EP1377164B1 (en) 2008-06-25
NZ528675A (en) 2006-10-27
ES2309166T3 (es) 2008-12-16
CN1499927A (zh) 2004-05-26
CA2443025A1 (en) 2002-10-17
PT1377164E (pt) 2008-09-30
EP1377164A1 (en) 2004-01-07
IL158155A (en) 2009-12-24
NO20034504L (no) 2003-12-09
RU2003132584A (ru) 2005-04-10
PL373361A1 (en) 2005-08-22
US20020169128A1 (en) 2002-11-14
HUP0303838A3 (en) 2010-03-29
US20110195046A1 (en) 2011-08-11
ATE399020T1 (de) 2008-07-15
IL198783A0 (en) 2010-02-17
NO20034504D0 (no) 2003-10-08
DK1377164T3 (da) 2008-10-13
CN101152565A (zh) 2008-04-02
WO2002080676A1 (en) 2002-10-17
HUP0303838A2 (hu) 2004-03-01
EP1377164A4 (en) 2005-05-04
DE60227244D1 (de) 2008-08-07
KR100885525B1 (ko) 2009-02-26
JP4428924B2 (ja) 2010-03-10
CN100379446C (zh) 2008-04-09
MXPA03009182A (es) 2004-02-17

Similar Documents

Publication Publication Date Title
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
BR0210056A (pt) composições e métodos para tratamento de hiperplasia
SE0001899D0 (sv) New compounds
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
KR950013511A (ko) 실금 치료
ATE442862T2 (de) Niederviskose konzentrierte proteinformulierungen
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
PT1173197E (pt) Intervencao metabolica com glp-1, para melhorar a funcao do tecido isquemico e reperfundido
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
BR0211011A (pt) Composição, método para fornecimento de estabilidade fìsica, método para tratamento de fibras queratìnicas e kit de múltiplos compartimentos
ZA953358B (en) New pharmaceutical composition based on taxoids
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
EP1354602A4 (en) MEDICAL COMPOSITIONS WITH DIURETIC AGENT AND IMPROVING INSULIN RESISTANCE
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
BRPI0413413A (pt) feniloxazolidinonas de piperidino substituìdo tendo atividade antimicrobiana com eficácia in vivo melhorada
BR0213372A (pt) Medicamento compreendendo combinação de derivado de traizaespiro[5,5]undecano com inibidor de citocromo p450 isozima 3a4 e/ou inibidor de glocoproteìna-p
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
DK1305037T3 (da) Smertestillende medikament
BRPI0506493A (pt) combinações terapêuticas
SE0004101D0 (sv) New use
BRPI0116865B8 (pt) composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
BR0108087A (pt) Método e composições para o tratamento de uma doença inflamatória
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
BR0210063A (pt) Composição estável e uso da mesma
ATE311891T1 (de) Cytidin-diphosphocholin gegen diabetische neuropathie

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 10A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.